The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countri
Go back to The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countri| Merck & Co. (NYSE: MRK) | Delayed: 118.84 +3.36 (2.91%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $116.53 | 52 Week Low | $47.97 | |||
| Day High | $119.03 | P/E | 80.84 | |||
| Day Low | $116.53 | EPS | $1.47 | |||
| Volume | 3,970,575 | |||||
